NRTIs’ effect on the sequence of mitochondrial
DNA HV 2 in HIV infected patients
NRTIs’ effect on the sequence of mitochondrial
DNA HV 2 in HIV infected patients
Ya-Song WU MD, PhD1,Xin-Yue CHEN MD2,Ying SHI PhD2,Hao WU MD2,De-Xi CHEN MD, PhD2,Yu SUN MD2,Fu-Jie ZHANG MD3,
1.Division of Treatment
and Care, National Center for AIDS/STD Control and Prevention, Chinese
Center for Disease Control and Prevention, Beijing 102206, China; 2.Center for Infectious
Diseases, Beijing You’an Hospital, Capital Medical University,
Beijing 100069, China; 3.Division of Treatment
and Care, National Center for AIDS/STD Control and Prevention, Chinese
Center for Disease Control and Prevention, Beijing 102206, China；Beijing Ditan Hospital,
Beijing 100015, China;
Abstract：Potent combination antiretroviral therapy (cART) has significantly improved the life expectancy of people living with human immunodeficiency virus (HIV), but it has many side effects such as lipodystrophy (LD), hepatic steatosis, and lactic acidosis. Nucleoside reverse transcriptase inhibitors (NRTIs) could damage the mitochondria by inhibiting the human DNA polymerase gamma, leading to mtDNA deletion. However, it remains uncertain whether NRTIs could induce the hypervariable region (HV) mutations of the D loop of mitochondria in Chinese HIV/AIDS patients, and whether that effect is different between individuals with and without LD. Hereby, 30 Chinese AIDS patients who were receiving antiretroviral drugs were recruited, among which 16 had symptomatic LD and 14 did not. Blood samples were collected prior to and after 96 weeks of treatment. Total DNA was extracted from peripheral blood mononuclear cells (PBMCs). Fragments of 728 bp in length containing HV 2 were amplified by standard polymerase chain reaction (PCR). Direct DNA-sequencing analysis techniques were used to detect mitochondrial sequence variants between paired longitudinal samples. Alterations were compared with the revised Cambridge Reference Sequence (rCRS) to determine mutation or polymorphism. Results showed that two years after ART, totally seven cases exhibited sequence variations, five individuals showed 73€A→G revised variation (two with and three without LD), while two cases of LD were found to have other nucleotide alterations. There was no new alteration in individuals without LD. In conclusion, NRTIs could induce mutation of mtDNA HV 2, which might contribute to the development of LD.
. NRTIs’ effect on the sequence of mitochondrial
DNA HV 2 in HIV infected patients[J]. Front. Med., 2010, 4(2): 177-184.
Ya-Song WU MD, PhD, Xin-Yue CHEN MD, Ying SHI PhD, Hao WU MD, De-Xi CHEN MD, PhD, Yu SUN MD, Fu-Jie ZHANG MD, . NRTIs’ effect on the sequence of mitochondrial
DNA HV 2 in HIV infected patients. Front. Med., 2010, 4(2): 177-184.
Kohler J J, Lewis W. A brief overviewof mechanisms of mitochondrial toxicity from NRTIs. Environ Mol Mutagen, 2007, 48(3―4): 166―172 doi: 10.1002/em.20223
Wu Y, Li N, Zhang T, Wu H, Huang C, Chen D. Mitochondrial DNA base excision repair and mitochondrialDNA mutation in human hepatic HuH-7 cells exposed to stavudine. Mutat Res, 2009, 664(1―2): 28―38 doi: 10.1016/j.mrfmmm.2009.02.006
Andrews R M, Kubacka I, Chinnery P F, Lightowlers R N, Turnbull D M, Howell N. Reanalysis and revision ofthe Cambridge reference sequence for human mitochondrial DNA. Nat Genet, 1999, 23(2): 147 doi: 10.1038/13779
Anderson S, Bankier A T, Barrell B G, de Bruijn M H, Coulson A R, Drouin J, Eperon I C, Nierlich D P, Roe B A, Sanger F, Schreier P H, Smith A J, Staden R, Young I G. Sequenceand organization of the human mitochondrial genome. Nature, 1981, 290(5806): 457―465 doi: 10.1038/290457a0
Barthelemy C, de Baulny H O, Lombes A. D-loop mutations in mitochondrialDNA: link with mitochondrial DNA depletion? Hum Genet, 2002, 110(5): 479―487 doi: 10.1007/s00439-002-0708-4
Martin A M, Hammond E, Nolan D, Pace C, Den Boer M, Taylor L, Moore H, Martinez O P, Christiansen F T, Mallal S. Accumulation of mitochondrial DNA mutations in humanimmunodeficiency virus-infected patients treated with nucleoside-analoguereverse-transcriptase inhibitors. Am JHum Genet, 2003, 72(3): 549―560 doi: 10.1086/367849
McComsey G, Tan D J, Lederman M, Wilson E, Wong L J. Analysis of the mitochondrialDNA genome in the peripheral blood leukocytes of HIV-infected patientswith or without lipoatrophy. AIDS, 2002, 16(4): 513―518 doi: 10.1097/00002030-200203080-00001
Timmermans E C, Tebas P, Ruiter J P, Wanders R J, de Ronde A, de Baar M P. Real-time nucleic acid sequence-based amplification assayto quantify changes in mitochondrial DNA concentrations in cell culturesand blood cells from HIV-infected patients receiving antiviral therapy. Clin Chem, 2006, 52(6): 979―987 doi: 10.1373/clinchem.2005.062901
Crum-Cianflone N, Hullsiek K H, Marconi V, Weintrob A, Ganesan A, Barthel R V, Fraser S, Agan B K, Wegner S. Trends in the incidence of cancers amongHIV-infected persons and the impact of antiretroviral therapy: a 20-yearcohort study. AIDS, 2009, 23(1): 41―50 doi: 10.1097/QAD.0b013e328317cc2d
Mercier S, Gueye N F, Cournil A, Fontbonne A, Copin N, Ndiaye I, Dupuy A M, Cames C, Sow P S, Ndoye I, Delaporte E, Simondon K B. Lipodystrophy and metabolic disorders in HIV-1-infected adults on4- to 9-year antiretroviral therapy in Senegal: a case-control study. J Acquir Immune Defic Syndr, 2009, 51(2): 224―230 doi: 10.1097/QAI.0b013e31819c16f4
Brinkman K, Smeitink J A, Romijn J A, Reiss P. Mitochondrial toxicity induced by nucleoside-analoguereverse-transcriptase inhibitors is a key factor in the pathogenesisof antiretroviral-therapy-related lipodystrophy. Lancet, 1999, 354(9184): 1112―1115 doi: 10.1016/S0140-6736(99)06102-4
Kakuda T N, Brundage R C, Anderson P L, Fletcher C V. Nucleoside reverse transcriptase inhibitor-induced mitochondrialtoxicity as an etiology for lipodystrophy. AIDS, 1999, 13(16): 2311―2312 doi: 10.1097/00002030-199911120-00019
Shikuma C M, Hu N, Milne C, Yost F, Waslien C, Shimizu S, Shiramizu B. MitochondrialDNA decrease in subcutaneous adipose tissue of HIV-infected individualswith peripheral lipoatrophy. AIDS, 2001, 15(14): 1801―1809 doi: 10.1097/00002030-200109280-00009
McComsey G A, Paulsen D M, Lonergan J T, Hessenthaler S M, Hoppel C L, Williams V C, Fisher R L, Cherry C L, White-Owen C, Thompson K A, Ross S T, Hernandez J E, Ross L L. Improvements in lipoatrophy, mitochondrial DNA levelsand fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS, 2005, 19(1): 15―23 doi: 10.1097/00002030-200501030-00002
Nolan D, Hammond E, Martin A, Taylor L, Herrmann S, McKinnon E, Metcalf C, Latham B, Mallal S. Mitochondrial DNA depletionand morphologic changes in adipocytes associated with nucleoside reversetranscriptase inhibitor therapy. AIDS, 2003, 17(9): 1329―1338 doi: 10.1097/00002030-200306130-00007
McComsey G, Bai R K, Maa J F, Seekins D, Wong L J. Extensive investigationsof mitochondrial DNA genome in treated HIV-infected subjects: beyondmitochondrial DNA depletion. J Acquir ImmuneDefic Syndr, 2005, 39(2): 181―188
Williams R S. Mitochondrial gene expression in mammalian striated muscle.Evidence that variation in gene dosage is the major regulatory event. J Biol Chem, 1986, 261(26): 12390―12394
Veltri K L, Espiritu M, Singh G. Distinct genomic copy numberin mitochondria of different mammalian organs. J Cell Physiol, 1990, 143(1): 160―164 doi: 10.1002/jcp.1041430122
